Novo Nordisk Initiates Post-Marketing Surveillance for Alhemo® in Haemophilia Patients
Novo Nordisk is conducting a post-marketing surveillance study on Alhemo® to assess its safety and effectiveness in real-world settings.
Therapeutic Area
Therapeutic area intelligence for B with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The European Commission has approved HYMPAVZI for treating hemophilia A or B in patients 12 years and older with inhibitors, based on Phase 3 data showing significant bleed reduction.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.